Table 4.
Antimicrobial resistance rate (%) of Uu and Mh infection in patients
| Uu | Mh | Uu & Mh | ||||
|---|---|---|---|---|---|---|
| Female | Male | Female | Male | Female | Male | |
| TET | 271 (6.7) | 37 (5.6) | 19 (14.1) | 1 (5.9) | 223 (25.5) | 15 (21.1) |
| LEV | 233 (5.8) | 24 (3.6)* | 60 (44.4) | 3 (17.6)* | 527 (60.2) | 31 (43.7)* |
| ERY | 629 (15.6) | 42 (6.4)* | 123 (91.1) | 10 (58.8)* | 850 (97.0) | 61 (85.9)* |
| JOS | 6 (0.2) | 2 (0.3) | 0 (0.0) | 1 (5.9) | 17 (1.9) | 3 (4.2) |
| DOX | 174 (4.3) | 25 (3.8) | 0 (0.0) | 0 (0.0) | 56 (6.4) | 7 (9.9) |
| CIP | 3046 (75.4) | 426 (64.6)* | 78 (57.8) | 6 (35.3)* | 809 (92.4) | 59 (83.1)* |
| OFX | 178 (4.4) | 14 (2.1)* | 53 (39.3) | 1 (5.9)* | 492 (56.2) | 23 (32.4)* |
| MIN | 167 (4.1) | 17 (2.6) | 3 (2.2) | 0 (0.0) | 62 (7.1) | 4 (5.6) |
| ROX | 265 (6.6) | 29 (4.4)* | 130 (96.3) | 12 (70.6)* | 832 (95.0) | 58 (81.7)* |
| AZM | 125 (3.1) | 11 (1.7)* | 129 (95.6) | 13 (76.5)* | 816 (93.2) | 60 (84.5)* |
| CLR | 116 (2.9) | 9 (1.4)* | 125 (92.6) | 13 (76.5)* | 818 (93.4) | 60 (84.5)* |
| SPA | 616 (15.3) | 20 (3.0)* | 47 (34.8) | 1 (5.9)* | 517 (59.0) | 13 (18.3)* |
| n | 4038 | 660 | 135 | 17 | 876 | 71 |
Abbreviations: AZM, azithromycin; CIP, ciprofloxacin; CLR, clarithromycin; DOX, doxycycline; ERY, erythromycin; JOS, josamycin; LEV, levofloxacin; Mh, Mycoplasma hominis; MIN, minocycline; OFX, ofloxacin; ROX, roxithromycin; SPA, sparfloxacin; TET, tetracycline; Uu, Ureaplasma urealyticum.
*
P < .05.